Axicabtagene ciloleucel approved for second-line treatment of large B-cell lymphoma
WHO monitors hepatitis of unknown origin in UK children
15 April 2022New knowledge on lymphoid cell maturity could lead to more effective IBD therapies
15 April 2022Axicabtagene ciloleucel approved for second-line treatment of large B-cell lymphoma
Axicabtagene ciloleucel (axi-cel; Yescarta) was approved for treatment of large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within a year of first-line chemotherapy, the U.S. Food and Drug Administration announced April 1.
